Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GANX

GANX - Gain Therapeutics, Inc. Stock Price, Fair Value and News

$1.96-0.10 (-4.85%)
Market Closed

19/100

GANX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

19/100

GANX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.64

Target 3M

$1.84

Target 6M

$1.74

GANX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GANX Price Action

Last 7 days

-0.5%

Last 30 days

-38.0%

Last 90 days

11.4%

Trailing 12 Months

-5.8%

GANX RSI Chart

GANX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GANX Valuation

Market Cap

70.8M

Price/Earnings (Trailing)

-3.65

Price/Sales (Trailing)

1.9K

EV/EBITDA

-3.46

Price/Free Cashflow

-4.09

GANX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.64

Target 3M

$1.84

Target 6M

$1.74

GANX Fundamentals

GANX Revenue

Revenue (TTM)

55.2K

GANX Earnings

Earnings (TTM)

-19.4M

Earnings Growth (Yr)

-17.81%

Earnings Growth (Qtr)

9.03%

GANX Profitability

EBT Margin

-32794.50%

Return on Equity

-328.15%

Return on Assets

-176.74%

Free Cashflow Yield

-24.45%

GANX Investor Care

Shares Dilution (1Y)

36.09%

Diluted EPS (TTM)

-0.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023150.3K55.2K55.2K55.2K
2022204.7K210.7K183.3K140.1K
202127.5K110.3K130.9K165.0K
202000028.9K
Get all data in R, Python etc through our Historical Stock Data APIs

About Gain Therapeutics, Inc.

GANX
Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
 CEO
 WEBSITEgaintherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES28

Gain Therapeutics, Inc. Frequently Asked Questions

GANX is the stock ticker symbol of Gain Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Gain Therapeutics, Inc. is 70.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check GANX's fair value in chart for subscribers.

The fair value guage provides a quick view whether GANX is over valued or under valued. Whether Gain Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Gain Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GANX.

As of Wed Jan 28 2026, GANX's PE ratio (Price to Earnings) is -3.65 and Price to Sales (PS) ratio is 1.93 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GANX PE ratio will change depending on the future growth rate expectations of investors.